Phase 3 Readout

GMAB: Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Ri

Name: Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Ri
Start: 2028-03-01
End: 2028-03-01

March 1, 2028 · epcoritamab. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: March 1, 2028
Company: Genmab A/S (GMAB)
Drug: epcoritamab

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Ri

March 1, 2028

GMAB overview →

Company: Genmab A/S (GMAB)
Drug: epcoritamab
Indication: Diffuse Large B-Cell Lymphoma